Claims for Patent: 6,353,151

Summary for Patent: 6,353,151

Title:	Transgenic model for heart failure
Abstract:	The present invention discloses a transgenic mouse that is a model for congestive heart failure. The disclosed mouse is a subset of a transgenic mouse line that is a model for hypertrophic cardiomyopathy. Also disclosed are a recombinant nucleic acid molecule encoding a transgene, and methods of using the transgenic mouse model to study congestive heart failure and conditions and treatments related thereto.
Inventor(s):	Leinwand; Leslie A. (Boulder, CO), Vikstrom; Karen L. (Fayetteville, NY)
Assignee:	University Technology Corporation (Boulder, CO)
Application Number:	08/938,105
Patent Claims:	1. A transgenic mouse useful for studying congestive heart failure, said transgenic mouse being at least about five months old and having incorporated into its genome a transgene comprising: (a) a heart tissue-specific promoter selected from the group consisting of mouse and rat .alpha. myosin heavy chain promoters; and (b) a nucleic acid sequence encoding an amino acid sequence of a mammalian .alpha. myosin heavy chain protein, said nucleic acid sequence having a first mutation comprising a point mutation which results in an Arg403Gln mutation in said amino acid sequence and a second mutation comprising an in-frame deletion of the portion of said nucleic acid sequence that encodes amino acids 468-527 of the actin binding domain bridged by an addition of a nucleic acid sequence encoding eight amino acid residues that do not encode a portion of said actin binding domain; wherein said transgene is expressed in the heart tissues of said transgenic mouse so that said transgenic mouse exhibits at least one phenotypic characteristic associated with congestive heart failure if it is a male. 2. The transgenic mouse of claim 1, wherein said addition of amino acid residues is represented by amino acid sequence SEQ ID NO:1. 3. The transgenic mouse of claim 1, wherein said nucleic acid sequence is SEQ ID NO:2. 4. The transgenic mouse of claim 1, wherein said amino acid sequence is SEQ ID NO:3. 5. The transgenic mouse of claim 1, wherein said heart tissue-specific promoter is a rat .alpha. myosin heavy chain promoter. 6. The transgenic mouse of claim 1, wherein said nucleic acid sequence further comprises an intron 5' to the encoding sequence and an intron 3' to the encoding and polyadenylation sequences. 7. The transgenic mouse of claim 1, wherein said .alpha. myosin heavy chain protein is from a rodent .alpha. myosin heavy chain selected from the group consisting of a rat and a mouse. 8. The transgenic mouse of claim 1, wherein said mouse is male. 9. The transgenic mouse of claim 1, wherein said mouse exhibits dilation of at least one heart chamber. 10. The transgenic mouse of claim 9, wherein said heart chamber is the left ventricle. 11. The transgenic mouse of claim 9, wherein said mouse has a left ventricular end-diastolic dimension (LVEDD) of between about 2.7 mm and about 4.0 mm. 12. The transgenic mouse of claim 9, wherein said mouse has heart walls that are at least about 10% thinner than heart walls of a mouse that does not carry said transgene. 13. The transgenic mouse of claim 9, wherein said mouse has heart walls that are at least 30% thinner than heart walls of a mouse that does not carry said transgene. 14. The transgenic mouse of claim 9, wherein said mouse has heart walls that are at least 50% thinner than heart walls of a mouse that does not carry said transgene. 15. The transgenic mouse of claim 9, wherein said mouse has heart walls that are at least 70% thinner than heart walls of a mouse that does not carry said transgene. 16. The transgenic mouse of claim 9, wherein said mouse does not exhibit cardiac hypertrophy. 17. The transgenic mouse of claim 9, wherein said mouse has reduced systolic function compared to a mouse that does not carry said transgene. 18. The transgenic mouse of claim 9, wherein said mouse has a systolic dysfunction indicated by a percent fractional shortening (% FS) of between about % FS=18 and about % FS=30. 19. The transgenic mouse of claim 2 wherein said .alpha. myosin heavy chain protein is from a rat .alpha. myosin heavy chain. 20. A recombinant nucleic acid molecule comprising a nucleic acid sequence encoding an amino acid sequence of an .alpha. myosin heavy chain protein, said nucleic acid sequence having a first mutation comprising a point mutation which results in an Arg403Gln mutation in said amino acid sequence and a second mutation comprising an in-frame deletion of a portion of said nucleic acid sequence that encodes an actin binding domain; wherein said nucleic acid sequence is operatively linked to one or more expression control sequences. 21. The recombinant nucleic acid molecule of claim 20, wherein one of said expression control sequences is a heart tissue-specific promoter selected from the group consisting of mouse and rat .alpha. myosin heavy chain promoters. 22. The recombinant nucleic acid molecule of claim 21, wherein said heart tissue-specific promoter is a rat or mouse .alpha. myosin heavy chain promoter. 23. The recombinant nucleic acid molecule of claim 20, wherein said in-frame deletion comprises a deletion of said nucleic acid sequence encoding at least about 15 amino acids of said actin binding domain. 24. The recombinant nucleic acid molecule of claim 20, wherein said in-frame deletion comprises a deletion in said nucleic acid sequence that encodes amino acid residues from about position 468 to about position 527 of said actin binding domain. 25. The recombinant nucleic acid molecule of claim 20, wherein said in-frame deletion is bridged by a nucleic acid sequence encoding an addition of amino acid residues that do not encode a portion of said actin binding domain of said .alpha. myosin protein. 26. The recombinant nucleic acid molecule of claim 20, wherein said nucleic acid sequence is SEQ ID NO:2. 27. The recombinant nucleic acid molecule of claim 20, wherein said amino acid sequence is SEQ ID NO:3. 28. The recombinant nucleic molecule of claim 21, wherein said heart tissue-specific promoter is a mouse .alpha. myosin heavy chain promoter. 29. The recombinant nucleic acid molecule of claim 24, wherein said in-frame deletion comprises a deletion of said nucleic acid sequence encoding at least about 15 amino acid residues from about position 468 to about position 527 of said actin binding domain. 30. The recombinant nucleic acid molecule of claim 29, wherein said in-frame deletion comprises a deletion of said nucleic acid sequence encoding all of said amino acid residues from about position 468 to about position 527 of said actin binding domain. 31. The recombinant nucleic acid molecule of claim 30, wherein said in-frame deletion is bridged by a nucleic acid sequence encoding an addition of amino acid residues that do not encode a portion of said actin binding domain. 32. The recombinant nucleic acid molecule of claim 31, wherein said addition of amino acid residues comprises an amino acid sequence of about 8 amino acid residues. 33. The recombinant nucleic acid molecule of claim 32, wherein said addition of amino acid residues is represented by amino acid SEQ ID NO:1. 34. The recombinant nucleic acid molecule of claim 21, wherein said expression control sequences further include 5' and 3' flanking introns and polyadenylation sequences. 35. The recombinant nucleic acid molecule of claim 22, wherein said heart tissue-specific promoter is a rat .alpha. myosin heavy chain promoter. 36. A method of screening compounds to determine their usefulness for treating or preventing congestive heart failure, comprising the steps of: (a) providing a male transgenic mouse having incorporated into its genome a transgene comprising a heart tissue-specific promoter selected from the group consisting of mouse and rat .alpha. myosin heavy chain promoters, and a nucleic acid sequence encoding an amino acid sequence of a mammalian .alpha. myosin heavy chain protein, said nucleic acid having a first mutation comprising a point mutation which results in an Arg403Gln mutation in said amino acid sequence and a second mutation comprising an in-frame deletion of the portion of said nucleic acid sequence that encodes amino acids 468-527 of the actin binding domain bridged by an addition of a nucleic acid sequence encoding eight amino acid residues that do not encode a portion of said actin binding domain; wherein said transgene is expressed in the heart tissues of said transgenic mouse so that when said transgenic mouse is at least about five months old, it exhibits at least one phenotypic characteristic associated with congestive heart failure; (b) administering a compound to be evaluated to the male transgenic mouse; and (c) evaluating a change in a phenotypic characteristic associated with congestive heart failure in said transgenic mouse compared to another transgenic mouse that did not receive said compound to determine the efficacy of said compound in treating or preventing congestive heart failure. 37. A method for evaluating the effects of external factors selected from the group consisting of diet and exercise on congestive heart failure, comprising the steps of: (a) establishing a normal control regimen for an external factor selected from the group consisting of diet and exercise in a first male transgenic mouse having incorporated into its genome a transgene comprising a heart tissue-specific promoter selected from the group consisting of mouse and rat .alpha. myosin heavy chain promoters, and a nucleic acid sequence encoding an amino acid sequence of a mammalian .alpha. myosin heavy chain protein, said nucleic acid sequence having a first mutation comprising a point mutation which results in an Arg403G1n mutation in said amino acid sequence and a second mutation comprising an in-frame deletion of the portion of said nucleic acid sequence that encodes amino acids 468-527 of the actin binding domain bridged by an addition of a nucleic acid sequence encoding 8 amino acid residues that do not encode a portion of said actin binding domain; (b) modulating said regimen for said external factor in a second male transgenic mouse having the same transgene as said first transgenic mouse; and (c) monitoring said second transgenic mouse for a change in a phenotypic characteristic associated with congestive heart failure compared to said first transgenic mouse.

Details for Patent 6,353,151

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2016-09-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2016-09-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2016-09-26